Pandemic-related disruptions to global supply chains and the effects of Russia's war in Ukraine have driven up prices of energy, commodities and necessities.
Expected FDA approval would make Leqembi the first in its class of drugs that work by removing sticky amyloid plaques from the brain to achieve the regulatory milestone.
European shares dipped on Thursday as rate-sensitive technology shares slipped on expectations of further interest rate hikes by major central banks, although gains in banks helped limit losses.
Novartis' soon-to-be spun off generics division Sandoz is expected to expand its pipeline and potentially generate an additional $3 billion in net sales over the next five years, the Swiss group said on Thursday.